Atlas Trials

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Clinical trial NCT04867616 · COMPLETED

Trial details

NCT number
NCT04867616
Sponsor
UCB Biopharma SRL
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Alzheimer's Disease
Start date
2021-06-09
Primary completion
2024-05-24
Enrollment
466

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.